ATE361993T1 - Diagnose und behandlung von prostatakrebs - Google Patents

Diagnose und behandlung von prostatakrebs

Info

Publication number
ATE361993T1
ATE361993T1 AT01960979T AT01960979T ATE361993T1 AT E361993 T1 ATE361993 T1 AT E361993T1 AT 01960979 T AT01960979 T AT 01960979T AT 01960979 T AT01960979 T AT 01960979T AT E361993 T1 ATE361993 T1 AT E361993T1
Authority
AT
Austria
Prior art keywords
hne
gated
voltage
nucleic acid
cancer
Prior art date
Application number
AT01960979T
Other languages
English (en)
Inventor
Mustafa Djamgoz
Scott Fraser
James Diss
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Application granted granted Critical
Publication of ATE361993T1 publication Critical patent/ATE361993T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01960979T 2000-09-02 2001-09-03 Diagnose und behandlung von prostatakrebs ATE361993T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0021617.6A GB0021617D0 (en) 2000-09-02 2000-09-02 Diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
ATE361993T1 true ATE361993T1 (de) 2007-06-15

Family

ID=9898761

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01960979T ATE361993T1 (de) 2000-09-02 2001-09-03 Diagnose und behandlung von prostatakrebs

Country Status (10)

Country Link
US (2) US20060166194A1 (de)
EP (1) EP1313882B1 (de)
JP (1) JP2004507254A (de)
AT (1) ATE361993T1 (de)
AU (1) AU2001282364A1 (de)
CY (1) CY1107715T1 (de)
DE (1) DE60128368T2 (de)
ES (1) ES2288979T3 (de)
GB (1) GB0021617D0 (de)
WO (1) WO2002018637A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002084284A2 (en) * 2001-04-12 2002-10-24 Imperial College Innovations Limited Diagnosis and treatment of cancer:ii
CA2443968A1 (en) * 2001-04-12 2002-10-24 Imperial College Innovations Limited Diagnosis and treatment of cancer: i
EP1711517A4 (de) * 2004-01-21 2008-02-13 Univ Utah Res Found MUTANTER NATRIUMKANAL NAv1.7 UND DAMIT VERBUNDENE VERFAHREN
ES2537631T3 (es) * 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
EP2589668A1 (de) 2006-06-14 2013-05-08 Verinata Health, Inc Analyse seltener Zellen mittels Probentrennung und DNA-Etiketten
EP2029779A4 (de) 2006-06-14 2010-01-20 Living Microsystems Inc Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
AU2008326497B2 (en) * 2007-11-19 2014-02-13 Genentech, Inc. Compositions and methods for inhibiting tumor progression
GB0811360D0 (en) * 2008-06-20 2008-07-30 Imp Innovations Ltd Methods
CA3069082C (en) 2008-09-20 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
CA2773983A1 (en) 2009-09-11 2011-03-17 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
US9636418B2 (en) 2013-03-12 2017-05-02 Amgen Inc. Potent and selective inhibitors of NAV1.7
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
EP3810776A1 (de) 2018-06-22 2021-04-28 F. Hoffmann-La Roche AG Oligonukleotide zur modulation der scn9a-expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204355C (en) * 1994-11-02 2001-01-16 Gail Mandel Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
US7399599B2 (en) * 2000-07-10 2008-07-15 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods

Also Published As

Publication number Publication date
US7759078B2 (en) 2010-07-20
WO2002018637A2 (en) 2002-03-07
ES2288979T3 (es) 2008-02-01
JP2004507254A (ja) 2004-03-11
DE60128368T2 (de) 2008-01-10
GB0021617D0 (en) 2000-10-18
CY1107715T1 (el) 2013-04-18
AU2001282364A1 (en) 2002-03-13
US20080145859A1 (en) 2008-06-19
WO2002018637A3 (en) 2002-11-21
US20060166194A1 (en) 2006-07-27
EP1313882B1 (de) 2007-05-09
DE60128368D1 (de) 2007-06-21
EP1313882A2 (de) 2003-05-28

Similar Documents

Publication Publication Date Title
ATE361993T1 (de) Diagnose und behandlung von prostatakrebs
WO2002083945A3 (en) Diagnosis and treatment of cancer: i
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE60134995D1 (de) Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden
ATE345399T1 (de) Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
WO2000052054A3 (en) Antibodies for cancer therapy and diagnosis
WO2004110345A8 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
ATE413881T1 (de) Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
Seebauer et al. Effects of cold physical plasma on oral lichen planus: an in vitro study (effects of CAP on OLP)
WO2000009754A3 (en) HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
ATE375389T1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
BR0312483A (pt) Anticorpos e seus usos
DE69920681D1 (de) Humaner k+ ionenkanal und therapeutische verwendungen davon
Schoser et al. A large german kindred with cold‐aggravated myotonia and a heterozygous A1481D mutation in the SCN4A gene
FR2756845B1 (fr) Sequence nucleotidique codant pour une flavine monooxygenase , proteine correspondante et composition destinee au diagnostic et a la therapie du glaucome
ATE390435T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
Laurence Experimental approach to the epidermal chalone
WO2001090156A3 (en) Card domain containing polypeptides, encoding nucleic acids, and methods of use
DE60035857D1 (de) Nukleinsäure- und aminosäuresequenzen von durch hämoglobin induzierbaren genen aus candida albicans und die verwendung dieser sequenzen in reagenzien zur diagnose von disseminierten candida albicans infektionen
WO2001016158A3 (en) Bridging integrator-2 (bin2) nucleic acid molecules and proteins and uses therefor
ATE397090T1 (de) Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen
WO2003084480A3 (en) HAUSP-p53 INTERACTION AND USES THEREOF

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties